(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.10% ¥ 1 015.00
Live Chart Being Loaded With Signals
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally...
Stats | |
---|---|
Объем за сегодня | 131 600 |
Средний объем | 353 120 |
Рыночная капитализация | 122.22B |
EPS | ¥0 ( 2024-02-14 ) |
Дата следующего отчета о доходах | ( ¥14.90 ) 2024-05-09 |
Last Dividend | ¥42.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 77.60 |
ATR14 | ¥0.702 (0.07%) |
Объем Корреляция
Takara Bio Inc. Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Takara Bio Inc. Корреляция - Валюта/Сырье
Takara Bio Inc. Финансовые показатели
Annual | 2022 |
Выручка: | ¥78.14B |
Валовая прибыль: | ¥44.77B (57.29 %) |
EPS: | ¥132.97 |
FY | 2022 |
Выручка: | ¥78.14B |
Валовая прибыль: | ¥44.77B (57.29 %) |
EPS: | ¥132.97 |
FY | 2022 |
Выручка: | ¥67.70B |
Валовая прибыль: | ¥49.21B (72.69 %) |
EPS: | ¥164.84 |
FY | 2021 |
Выручка: | ¥46.09B |
Валовая прибыль: | ¥31.87B (69.16 %) |
EPS: | ¥79.29 |
Financial Reports:
No articles found.
Takara Bio Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥42.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.000 | 2012-03-28 |
Last Dividend | ¥42.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 13 | -- |
Total Paid Out | ¥114.10 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.76 | -- |
Div. Sustainability Score | 8.16 | |
Div.Growth Potential Score | 6.07 | |
Div. Directional Score | 7.11 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9368.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8242.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7609.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
6807.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6151.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4887.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4062.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3282.T | Ex Dividend Junior | 2024-01-30 | Semi-Annually | 0 | 0.00% | |
2325.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9948.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0330 | 1.500 | 9.34 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0128 | 1.200 | 9.57 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0141 | 1.500 | -0.954 | -1.431 | [0.1 - 1] |
payoutRatioTTM | 3.21 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 7.45 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.46 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.25 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 61.42 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 200.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 81.73 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.553 | 1.000 | 4.11 | 4.11 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0309 | 1.000 | -1.382 | -1.382 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.387 | 0.800 | -0.751 | -0.601 | [0.5 - 2] |
Total Score | 8.16 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 77.80 | 1.000 | 2.24 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0141 | 2.50 | -0.613 | -1.431 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 81.73 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.675 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 200.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 3.21 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 53.88 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.506 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 6.07 |
Takara Bio Inc.
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа